CONTACT A REP
Patients HCP
This site is for US Health Care Professionals only.

She's worried. And rightly so.

For patients like her, with stage II or III HR+/HER2- eBC, risk of recurrence isn’t a fleeting thought. It’s a persistent concern—one that she’ll live with for the rest of her life.1

Despite treatment with adjuvant ET, patients with stage II/III HR+/HER2- eBC remain at risk of recurrence with incurable metastatic disease—even if they have no or low nodal involvement.2-4

eBC, early breast cancer; ET, endocrine therapy; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive.

Risk is real. Just how real, exactly?

Risk of recurrence within 3 years 3,4

Image describing recurrence risk by nodal status within 3 years, for patients with stage II or III HR+/HER2- eBC. Recurrence risk with N0 disease (no nodal involvement) up to 1 in 9. With N1 disease (1-3 nodes): up to 1 in 8. With N2/N3 disease (4+ nodes): up to 1 in 4.

The 3-year risk of recurrence rates are based on iDFS outcomes published for patients with HR+/HER2- eBC in select CDK4/6 inhibitor clinical trials, who were also treated with standard ET, including tamoxifen. KISQALI is not indicated for concomitant use with tamoxifen due to an increased risk for QT prolongation. Data are from control arms only; no comparisons should be made between results from CDK4/6 inhibitor trial arms.3-5

CDK, cyclin-dependent kinase; iDFS, invasive disease-free survival; N, nodal status.

Know the risk to know what’s next

Include a range of factors for a more accurate estimate of risk that can help guide your treatment approach
Key factors for consideration include clinical factors and genomic factors. Clinical factors: anatomic stage, histological grade, tumor size, nodal status, and Ki-67 score. Genomic factors include genomic profile scores. Patient age and menopausal status may also impact interpretation of genomic profile scores.

She’s worried that her cancer may come back.
 
What if you could do MORE for her?

DO MORE TODAY
Resource thumbnail

Check all the boxes: Make sure to consider a range of factors when evaluating risk

A lot of factors go into assessing risk. Review this checklist for a comprehensive risk assessment.
Download
Resource thumbnail

Risk isn’t something she can ignore, but facing it can be difficult​

Review this guide for help addressing some of the common patient questions around risk of recurrence.
Download
Resource thumbnail

Help your colleagues recognize the real risk to their patients​

Keep this information handy in a shareable digital format for easy reference around your practice.
Download
References: 1. Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol. 2016;14(1):223. doi:10.1186/s12957-016-0988-0 2. Slamon DJ, Fasching PA, Hurvitz S, et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer. Ther Adv Med Oncol. 2023;15:1-16. doi:10.1177/17588359231178125 3. Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212-222. doi:10.1016/S1470-2045(20)30642-2 4. Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77-90. doi:10.1016/S1470-2045(22)00694-5 5. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp.​ 6. Amin MB, Edge SB, Greene FL, et al, eds; American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2017.